Radiotherapy in the Management of Prostate Cancer

  • Melvin Lee Kiang Chua
  • Jure Murgic
  • E. Brian Butler
  • Bin S. TehEmail author
Part of the Medical Radiology book series (MEDRAD)


Prostate cancer remains one of the most common cancer diagnoses among men in North America. The majority are treated with surgery or radiotherapy; and the advent of technological precision has driven remarkable improvements in clinical outcomes. Here, we highlight existing controversies surrounding the use of radiotherapy in the management of prostate cancer, with specific focus on different clinical scenarios.


  1. Abdollah F, Cozzarini C, Sun M et al (2013) Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiother Oncol 109(2):211–216CrossRefPubMedPubMedCentralGoogle Scholar
  2. Abdollah F, Karnes RJ, Suardi N et al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32(35):3939–3947CrossRefPubMedPubMedCentralGoogle Scholar
  3. Aizer AA, Yu JB, McKeon AM et al (2009) Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 75(5):1344–1349CrossRefPubMedPubMedCentralGoogle Scholar
  4. Al-Mamgani A, van Putten WL, Heemsbergen WD et al (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988CrossRefPubMedPubMedCentralGoogle Scholar
  5. Al-Mamgani A, Heemsbergen WD, Peeters ST et al (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73(3):685–691CrossRefPubMedPubMedCentralGoogle Scholar
  6. Aluwini S, Pos F, Schimmel E et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16(3):274–283CrossRefPubMedPubMedCentralGoogle Scholar
  7. Andriole GL, Crawford ED, Grubb RL 3rd et al (2009) PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319CrossRefPubMedPubMedCentralGoogle Scholar
  8. Andriole GL, Crawford ED, Grubb RL 3rd et al.; PLCO Project Team (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125–132Google Scholar
  9. Antonarakis ES, Feng Z, Trock BJ et al (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109(1):32–39CrossRefPubMedPubMedCentralGoogle Scholar
  10. Arcangeli G, Saracino B, Gomellini S et al (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78(1):11–18Google Scholar
  11. Arcangeli S, Strigari L, Gomellini S et al (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1172–1178CrossRefPubMedPubMedCentralGoogle Scholar
  12. Asbell SO, Krall JM, Pilepich MV et al (1988) Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15(6):1307–1316CrossRefPubMedPubMedCentralGoogle Scholar
  13. Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40(4):769–782CrossRefPubMedPubMedCentralGoogle Scholar
  14. Beckendorf V, Guerif S, Le Prisé E et al (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063CrossRefPubMedPubMedCentralGoogle Scholar
  15. Bekelman JE, Hahn SM (2014) Reference pricing with evidence development: a way forward for proton therapy. J Clin Oncol 32(15):1540–1542CrossRefPubMedPubMedCentralGoogle Scholar
  16. Bill-Axelson A, Holmberg L, Ruutu M et al.; SPCG-4 Investigators (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717Google Scholar
  17. Bill-Axelson A, Holmberg L, Garmo H et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932–942CrossRefPubMedPubMedCentralGoogle Scholar
  18. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327):103–106CrossRefPubMedPubMedCentralGoogle Scholar
  19. Bolla M, van Poppel H, Collette L et al.; European Organization for Research and Treatment of Cancer (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572–578Google Scholar
  20. Bolla M, de Reijke TM, Van Tienhoven G et al.; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527Google Scholar
  21. Bolla M, van Poppel H, Tombal B et al.; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–2027Google Scholar
  22. Bolla M, Maingon P, Carrie C et al (2016) Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol 34(15):1748–1756Google Scholar
  23. Boorjian SA, Thompson RH, Siddiqui S et al (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178(3 Pt 1):864–870CrossRefPubMedPubMedCentralGoogle Scholar
  24. Boorjian SA, Karnes RJ, Viterbo R et al (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117(13):2883–2891CrossRefPubMedPubMedCentralGoogle Scholar
  25. Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101CrossRefPubMedPubMedCentralGoogle Scholar
  26. Briganti A, Chun FK, Karakiewicz PI et al (2008) Is node-positive prostate cancer always a systemic disease? Eur Urol 54(2):243–246CrossRefPubMedPubMedCentralGoogle Scholar
  27. Briganti A, Karnes JR, Da Pozzo LF et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55(2):261–270CrossRefPubMedPubMedCentralGoogle Scholar
  28. Briganti A, Larcher A, Abdollah F et al (2012a) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487CrossRefPubMedPubMedCentralGoogle Scholar
  29. Briganti A, Wiegel T, Joniau S et al (2012b) Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 62(3):472–487CrossRefPubMedPubMedCentralGoogle Scholar
  30. Carlsson SV, Tafe LJ, Chade DC et al (2013) Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol 189(4):1314–1318CrossRefPubMedPubMedCentralGoogle Scholar
  31. Cheng L, Zincke H, Blute ML et al (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91(1):66–73CrossRefPubMedPubMedCentralGoogle Scholar
  32. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28(7):1117–1123CrossRefPubMedPubMedCentralGoogle Scholar
  33. Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65(6):1058–1066CrossRefPubMedPubMedCentralGoogle Scholar
  34. D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRefPubMedPubMedCentralGoogle Scholar
  35. D'Amico AV, Manola J, Loffredo M et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292(7):821–827CrossRefPubMedPubMedCentralGoogle Scholar
  36. Dasu A, Toma-Dasu I (2012) Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 51(8):963–974CrossRefPubMedPubMedCentralGoogle Scholar
  37. Dearnaley D, Syndikus I, Sumo G et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13(1):43–54CrossRefPubMedPubMedCentralGoogle Scholar
  38. Dearnaley DP, Jovic G, Syndikus I et al (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15(4):464–473CrossRefPubMedPubMedCentralGoogle Scholar
  39. Dearnaley DP, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1046–1060Google Scholar
  40. Den RB, Feng FY, Showalter TN et al (2014) Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 89(5):1038–1046CrossRefPubMedPubMedCentralGoogle Scholar
  41. Den RB, Yousefi K, Trabulsi EJ et al (2015) Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33(8):944–951CrossRefPubMedPubMedCentralGoogle Scholar
  42. Denham JW, Steigler A, Lamb DS et al.; Trans-Tasman Radiation Oncology Group (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6(11):841–850Google Scholar
  43. Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185(3):869–875CrossRefPubMedPubMedCentralGoogle Scholar
  44. Engel J, Bastian PJ, Baur H et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57(5):754–761CrossRefPubMedPubMedCentralGoogle Scholar
  45. Evans JR, Zhao SG, Chang SL, et al. (2016) Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer. JAMA Oncol 2:1–10. doi:  10.1001/jamaoncol.2015.4955. [Epub ahead of print]
  46. Freedland SJ, Rumble RB, Finelli A, et al.; American Society of Clinical Oncology (2014) Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 32(34):3892–3898Google Scholar
  47. Gakis G, Boorjian SA, Briganti A et al (2014) The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 66(2):191–199CrossRefPubMedPubMedCentralGoogle Scholar
  48. Galalae RM, Martinez A, Mate T et al (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58(4):1048–1055CrossRefPubMedPubMedCentralGoogle Scholar
  49. Gerber GS, Thisted RA, Chodak GW et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32(4):385–390CrossRefPubMedPubMedCentralGoogle Scholar
  50. Gray PJ, Paly JJ, Yeap BY et al (2013) Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119(9):1729–1735CrossRefPubMedPubMedCentralGoogle Scholar
  51. Grimm MO, Kamphausen S, Hugenschmidt H et al (2002) Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 41(6):628–634CrossRefPubMedPubMedCentralGoogle Scholar
  52. Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29CrossRefPubMedPubMedCentralGoogle Scholar
  53. Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357CrossRefPubMedPubMedCentralGoogle Scholar
  54. Heemsbergen WD, Al-Mamgani A, Slot A et al (2014) Long-term results of the Dutch randomized prostate cancer: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 110(1):104–109CrossRefPubMedPubMedCentralGoogle Scholar
  55. Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37CrossRefPubMedPubMedCentralGoogle Scholar
  56. Heijnsdijk EA, Wever EM, Auvinen A et al (2012) Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 367(7):595–605CrossRefPubMedPubMedCentralGoogle Scholar
  57. Herbert C, Liu M, Tyldesley S et al (2012) Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%. Int J Radiat Oncol Biol Phys 83(1):22–27CrossRefPubMedPubMedCentralGoogle Scholar
  58. Hoffman KE, Voong KR, Pugh TJ et al (2014) Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88(5):1074–1084Google Scholar
  59. Hong MK, Macintyre G, Wedge DC et al (2015) Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605CrossRefPubMedPubMedCentralGoogle Scholar
  60. Hoppe BS, Michalski JM, Mendenhall NP et al (2014) Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120(7):1076–1082CrossRefPubMedPubMedCentralGoogle Scholar
  61. Horwitz EM, Bae K, Hanks GE et al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26(15):2497–2504CrossRefPubMedPubMedCentralGoogle Scholar
  62. Hoskin PJ, Rojas AM, Bownes PJ et al (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103(2):217–222CrossRefPubMedPubMedCentralGoogle Scholar
  63. Iyengar P, Levy LB, Choi S et al (2011) Toxicity associated with postoperative radiation therapy for prostate cancer. Am J Clin Oncol 34(6):611–618CrossRefPubMedPubMedCentralGoogle Scholar
  64. Jacob R, Hanlon AL, Horwitz EM et al (2005) Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61(3):695–701CrossRefPubMedPubMedCentralGoogle Scholar
  65. James ND, Spears MR, Clarke NW et al.; STAMPEDE Investigators (2015a) Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol:1–10. doi:  10.1001/jamaoncol.2015.4350. [Epub ahead of print]
  66. James ND, Spears MR, Clarke NW et al (2015b) Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67(6):1028–1038CrossRefPubMedPubMedCentralGoogle Scholar
  67. Jones CU, Hunt D, McGowan DG et al (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365(2):107–118CrossRefPubMedPubMedCentralGoogle Scholar
  68. Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68(1):121–125CrossRefPubMedPubMedCentralGoogle Scholar
  69. Kattan MW, Zelefsky MJ, Kupelian PA et al (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21(24):4568–4571CrossRefPubMedPubMedCentralGoogle Scholar
  70. Kim DW, Cho LC, Straka C et al (2014) Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89(3):509–517CrossRefPubMedPubMedCentralGoogle Scholar
  71. Koukourakis G, Kelekis N, Armonis V et al (2009) Brachytherapy for prostate cancer: a systematic review. Adv Urol 2009:327945. doi: 10.1155/2009/327945CrossRefPubMedCentralGoogle Scholar
  72. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74CrossRefPubMedPubMedCentralGoogle Scholar
  73. Kuban DA, Levy LB, Cheung MR et al (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79(5):1310–1317CrossRefPubMedPubMedCentralGoogle Scholar
  74. Kupelian PA, Elshaikh M, Reddy CA et al (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20(16):3376–3385CrossRefPubMedPubMedCentralGoogle Scholar
  75. Lalonde E, Ishkanian AS, Sykes J et al (2014) Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 15(13):1521–1532CrossRefPubMedPubMedCentralGoogle Scholar
  76. Lane JA, Hamdy FC, Martin RM et al (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 46(17):3095–3101CrossRefPubMedPubMedCentralGoogle Scholar
  77. Lane JA, Donovan JL, Davis M et al.; ProtecT study group (2014) Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 15(10):1109–1118.Google Scholar
  78. Lawrence TS, Feng M (2013) Protons for prostate cancer: the dream versus the reality. J Natl Cancer Inst 105(1):7–8CrossRefPubMedPubMedCentralGoogle Scholar
  79. Lawton CA, Winter K, Grignon D et al (2005) Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31. J Clin Oncol 23(4):800–807CrossRefPubMedPubMedCentralGoogle Scholar
  80. Lawton CA, DeSilvio M, Roach M 3rd et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646–655CrossRefPubMedPubMedCentralGoogle Scholar
  81. Lawton CA, Michalski J, El-Naqa I et al (2009) RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74(2):383–387CrossRefPubMedPubMedCentralGoogle Scholar
  82. Lee WR, Dignam JJ, Amin MB et al (2016) Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 34(20):2325–2332Google Scholar
  83. Lin CC, Gray PJ, Jemal A, Efstathiou JA (2015) Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst 107(7)Google Scholar
  84. Lukka H, Hayter C, Julian JA et al (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23:6132–6138CrossRefPubMedPubMedCentralGoogle Scholar
  85. Mantini G, Tagliaferri L, Mattiucci GC et al (2011) Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys 81(5):e721–e726CrossRefPubMedPubMedCentralGoogle Scholar
  86. Martinez AA, Gustafson G, Gonzalez J et al (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53(2):316–327CrossRefPubMedPubMedCentralGoogle Scholar
  87. Martinez AA, Gonzalez J, Ye H et al (2011) Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79(2):363–370CrossRefPubMedPubMedCentralGoogle Scholar
  88. Mason MD, Parulekar WR, Sydes MR et al (2015) Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol 33(19):2143–2150CrossRefPubMedPubMedCentralGoogle Scholar
  89. Mendenhall NP, Hoppe BS, Nichols RC et al (2014) Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 88(3):596–602CrossRefPubMedPubMedCentralGoogle Scholar
  90. Messing EM, Manola J, Yao J et al.; Eastern Cooperative Oncology Group study EST 3886 (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7(6):472–479.Google Scholar
  91. Michalski JM, Yan Y, Watkins-Bruner D et al (2013) Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 87(5):932–938CrossRefPubMedPubMedCentralGoogle Scholar
  92. Michalski JM, Moughan J, Purdy JA et al (2014) Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126). Int J Radiat Oncol Biol Phys 90(5):1263Google Scholar
  93. Michalski JM, Moughan J, Purdy J et al (2015) A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. J Clin Oncol 33(suppl 7; abstr 4)Google Scholar
  94. Milecki P, Baczyk M, Skowronek J et al (2009) Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. J Biomed Biotechnol 2009:625394CrossRefPubMedPubMedCentralGoogle Scholar
  95. Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17–e24CrossRefPubMedPubMedCentralGoogle Scholar
  96. Mitchell JM (2013) Urologists’ use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med 369(17):1629–1637CrossRefPubMedPubMedCentralGoogle Scholar
  97. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV (2014) Prostate cancer, version 2.2014. J Natl Compr Canc Netw 12(5):686–718CrossRefPubMedPubMedCentralGoogle Scholar
  98. Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C et al (2011) Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 100(3):463–467CrossRefPubMedPubMedCentralGoogle Scholar
  99. Nabid A, Carrier N, Martin AG et al. (2013) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized trial. J Clin Oncol 31(suppl; abstr LBA4510)Google Scholar
  100. Nabid A, Carrier N, Vigneault E, Souhami L, Lemaire C, Brassard MA (2015) Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: a phase III trial. J Clin Oncol 33(suppl 7; abstr 5)Google Scholar
  101. Nguyen PL, Chen MH, Hoffman KE et al (2009) Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 74(1):104–109CrossRefPubMedPubMedCentralGoogle Scholar
  102. Ost P, Jereczek-Fossa BA, As NV et al (2016) Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a Multi-institutional Analysis. Eur Urol 69(1):9–12CrossRefPubMedPubMedCentralGoogle Scholar
  103. Pan CC, Kim KY, Taylor JM et al (2002) Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53(5):1139–1145CrossRefPubMedPubMedCentralGoogle Scholar
  104. Parikh R, Sher DJ (2012) Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis. Cancer 118(1):258–267CrossRefPubMedPubMedCentralGoogle Scholar
  105. Parker C, Sydes MR, Catton C, et al.; (RADICALS Trial Management Group) (2007) Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 99(6):1376–1379Google Scholar
  106. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58(6):843–848CrossRefPubMedPubMedCentralGoogle Scholar
  107. Pearse M, Fraser-Browne C, Davis ID et al (2014) A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial. BJU Int 113(Suppl 2):7–12CrossRefPubMedPubMedCentralGoogle Scholar
  108. Peinemann F, Grouven U, Hemkens LG et al (2011) Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev (7):CD008871Google Scholar
  109. Pfister D, Bolla M, Briganti A et al (2014) Early salvage radiotherapy following radical prostatectomy. Eur Urol 65(6):1034–1043CrossRefPubMedPubMedCentralGoogle Scholar
  110. Pollack A, Zagars GK, Smith LG et al (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18(23):3904–3911CrossRefPubMedPubMedCentralGoogle Scholar
  111. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105CrossRefPubMedPubMedCentralGoogle Scholar
  112. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31(31):3860–3868CrossRefPubMedPubMedCentralGoogle Scholar
  113. Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25(34):5366–5373CrossRefPubMedPubMedCentralGoogle Scholar
  114. Porter CR, Kodama K, Gibbons RP et al (2006) 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176(2):569–574CrossRefPubMedPubMedCentralGoogle Scholar
  115. Potosky AL, Miller BA, Albertsen PC et al (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273(7):548–552CrossRefPubMedPubMedCentralGoogle Scholar
  116. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597CrossRefPubMedPubMedCentralGoogle Scholar
  117. Resnick MJ, Koyama T, Fan KH et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368(5):436–445CrossRefPubMedPubMedCentralGoogle Scholar
  118. Roach M 3rd, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28(1):33–37CrossRefPubMedPubMedCentralGoogle Scholar
  119. Roach M 3rd, DeSilvio M, Lawton C et al.; Radiation Therapy Oncology Group 9413 (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21(10):1904–1911.Google Scholar
  120. Roobol MJ, Bokhorst LP (2014) The ProtecT trial: what can we expect? Lancet Oncol 15(10):1046–1047CrossRefPubMedPubMedCentralGoogle Scholar
  121. Rusthoven CG, Carlson JA, Waxweiler TV et al (2014) The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys 88(5):1064–1073CrossRefPubMedPubMedCentralGoogle Scholar
  122. Schmidt-Hansen M, Hoskin P, Kirkbride P et al (2014) Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. Clin Oncol (R CollRadiol) 26(10):e21–e46CrossRefGoogle Scholar
  123. Schröder FH, Hugosson J, Roobol MJ et al.; ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328.Google Scholar
  124. Schröder FH, Hugosson J, Roobol MJ et al (2012) ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990CrossRefPubMedPubMedCentralGoogle Scholar
  125. Schröder FH, Hugosson J, Roobol MJ et al.; for the ERSPC Investigators (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959):2027–2035.Google Scholar
  126. Schumacher MC, Burkhard FC, Thalmann GN et al (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54(2):344–352CrossRefPubMedPubMedCentralGoogle Scholar
  127. Seaward SA, Weinberg V, Lewis P et al (1998a) Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42(5):1055–1062CrossRefPubMedPubMedCentralGoogle Scholar
  128. Seaward SA, Weinberg V, Lewis P et al (1998b) Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am 4(6):370–377PubMedPubMedCentralGoogle Scholar
  129. Sheets NC, Goldin GH, Meyer AM et al (2012) Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307(15):1611–1620CrossRefPubMedPubMedCentralGoogle Scholar
  130. Sineshaw HM, Gray PJ, Efstathiou JA et al (2015) Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. Eur Urol 68(5):768–774Google Scholar
  131. Sooriakumaran P, Nyberg T, Akre O et al (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348:g1502. doi: 10.1136/bmj.g1502CrossRefPubMedPubMedCentralGoogle Scholar
  132. Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041CrossRefPubMedPubMedCentralGoogle Scholar
  133. Steuber T, Budäus L, Walz J et al (2011) Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 107(11):1755–1761CrossRefPubMedPubMedCentralGoogle Scholar
  134. Swanson GP, Thompson IM, Basler J (2006) Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 107(3):439–450CrossRefPubMedPubMedCentralGoogle Scholar
  135. Taylor A, Rockall AG, Powell ME (2007) An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clin Oncol (R Coll Radiol) 19(7):542–550CrossRefGoogle Scholar
  136. Thompson IM, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296(19):2329–2335CrossRefPubMedPubMedCentralGoogle Scholar
  137. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962CrossRefPubMedPubMedCentralGoogle Scholar
  138. Touijer KA, Mazzola CR, Sjoberg DD et al (2014) Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65(1):20–25CrossRefPubMedPubMedCentralGoogle Scholar
  139. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299(23):2760–2769CrossRefPubMedPubMedCentralGoogle Scholar
  140. Tward JD, Kokeny KE, Shrieve DC (2013) Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol 3(3):234–240CrossRefPubMedPubMedCentralGoogle Scholar
  141. Valicenti RK, Thompson I Jr, Albertsen P et al.; American Society for Radiation Oncology/American Urological Association (2013) Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys 86(5):822–828.Google Scholar
  142. van den Bergh RC, Ahmed HU, Bangma CH et al (2014) Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 65(6):1023–1031CrossRefPubMedPubMedCentralGoogle Scholar
  143. Van der Kwast T, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178–4186CrossRefPubMedPubMedCentralGoogle Scholar
  144. Viers BR, Sukov WR, Gettman MT et al (2014) Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Eur Urol 66(6):1116–1124CrossRefPubMedPubMedCentralGoogle Scholar
  145. Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85(1):89–94CrossRefPubMedPubMedCentralGoogle Scholar
  146. von Bodman C, Godoy G, Chade DC et al (2010) Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol 184(1):143–148CrossRefGoogle Scholar
  147. Wallis CJD, Saskin R, Choo R et al (2015) Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70(1):21–30CrossRefPubMedPubMedCentralGoogle Scholar
  148. Warde P, Mason M, Ding K et al.; NCIC CTG PR.3/MRC UK PR07 investigators (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378(9809):2104–2111Google Scholar
  149. Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101(19):1325–1329CrossRefPubMedPubMedCentralGoogle Scholar
  150. Widmark A, Klepp O, Solberg A et al.; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3 (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308Google Scholar
  151. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27(18):2924–2930CrossRefPubMedPubMedCentralGoogle Scholar
  152. Wiegel T, Bartkowiak D, Bottke D et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66(2):243–250CrossRefPubMedPubMedCentralGoogle Scholar
  153. Wiegel T, Bartkowiak D, Bottke D et al (2015) Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year Data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys 91(2):288–294CrossRefPubMedPubMedCentralGoogle Scholar
  154. Wilt TJ, Brawer MK, Jones KM et al.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203–213.Google Scholar
  155. Yeoh EE, Holloway RH, Fraser RJ et al (2006) Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66:1072–1083Google Scholar
  156. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J (2011) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81(5):1271–1278CrossRefPubMedPubMedCentralGoogle Scholar
  157. Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP et al (2014) Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 32(12):1195–1201CrossRefPubMedPubMedCentralGoogle Scholar
  158. Zagars GK, Pollack A, von Eschenbach AC (2001) Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58(2):233–239CrossRefPubMedPubMedCentralGoogle Scholar
  159. Zapatero A, Guerrero A, Maldonado J et al (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16(3):320–327CrossRefPubMedPubMedCentralGoogle Scholar
  160. Zelefsky MJ, Leibel SA, Gaudin PB et al (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41(3):491–500CrossRefPubMedPubMedCentralGoogle Scholar
  161. Zelefsky MJ, Eastham JA, Cronin AM et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28(9):1508–1513CrossRefPubMedPubMedCentralGoogle Scholar
  162. Zelefsky MJ, Pei X, Chou JF et al (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60(6):1133–1139CrossRefPubMedPubMedCentralGoogle Scholar
  163. Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28(7):1106–1111CrossRefPubMedPubMedCentralGoogle Scholar
  164. Zumsteg ZS, Spratt DE, Pei I et al (2013) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64(6):895–902CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Melvin Lee Kiang Chua
    • 1
    • 2
    • 3
  • Jure Murgic
    • 4
  • E. Brian Butler
    • 5
  • Bin S. Teh
    • 5
    Email author
  1. 1.Division of Radiation OncologyNational Cancer CentreSingaporeSingapore
  2. 2.Duke-NUS Graduate Medical SchoolSingaporeSingapore
  3. 3.Radiation Medicine Program, Princess Margaret Cancer CentreTorontoCanada
  4. 4.Department of Oncology and Nuclear MedicineUniversity Hospital Sisters of Charity, University of Zagreb Medical SchoolZagrebCroatia
  5. 5.Department of Radiation OncologyHouston Methodist Hospital, Cancer Center and Research Institute, Weil Cornell Medical CollegeHoustonUSA

Personalised recommendations